Infliximab therapy in an infant with Netherton Syndrome.

Abstract

We present a patient with Netherton syndrome and severe skin manifestations treated with infliximab. By 6\xa0months of age, the child had intractable pruritus, scaling, dry skin, and generalized eczematous lesions resistant to conventional therapies for atopic dermatitis. Clinical improvement was observed following the third infusion of infliximab, and by 12\xa0months of age, the skin lesions completely resolved. Infliximab is a promising option for the management of skin inflammation in Netherton syndrome, even in infants.